Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
NAGA Sees Bitcoin Correction Before Potential Q4 Rally

NAGA Sees Bitcoin Correction Before Potential Q4 Rally

BitgetBitget2026/10/20 16:30
  • NAGA’s Q4 2026 outlook is neutral on Bitcoin and Ether, with overbought conditions signaling a correction before potential further gains.
  • A risk-off scenario carries a 50% probability, potentially pressuring cryptocurrencies; USD 81,000 is Bitcoin’s key level.
  • Dollar strength and a dollar correction each carry 25% probabilities, respectively pressuring and supporting cryptocurrencies.
  • Bitcoin rose 42.7% in Q3; Ether gained 71.3%, though both remained down year-to-date through September 30.
  • Spot Bitcoin ETFs attracted USD 6.3 billion in Q3 net inflows, reversing about USD 5 billion in Q2 outflows.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The NAGA Group AG published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks